Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$90.07 USD

90.07
635,290

-0.63 (-0.69%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $90.16 +0.09 (0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

by Zacks Equity Research

Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research

On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.

Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Editas (EDIT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.

Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Kevin Cook headshot

Alzheimer's Disease: 5 Stocks on Biotech Radars

by Kevin Cook

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus

by Zacks Equity Research

Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.

Kevin Cook headshot

Biotech Bonanza: COVID Launches Science at Warp Speed

by Kevin Cook

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.

Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study

by Zacks Equity Research

Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.

Why Is Axsome (AXSM) Up 15.2% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.

Axsome Expedites Development Plan for Narcolepsy Candidate

by Zacks Equity Research

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's NDA Filing for Migraine Candidate in Q4 on Track

by Zacks Equity Research

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.

Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020

by Zacks Equity Research

Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.

Axsome's NDA for Depressive Disorder Drug on Track in Q420

by Zacks Equity Research

Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.

Axsome's AXS-05 Gets Breakthrough Therapy Tag for AD Agitation

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Axsome's (AXSM) AXS-05 for the treatment of Alzheimer's disease agitation. Shares rise.

Company News for Jun 29, 2020

by Zacks Equity Research

Companies in the news are: GPS, CLGX, AXSM, VXRT

Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses

by Zacks Equity Research

Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.

Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study

by Zacks Equity Research

Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.